 NEWARK, Calif., Dec. 6, 2020 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq:PTGX today announced additional updated results from the ongoing Phase 2 study of PTG-300 in patients with polycythemia vera PV, demonstrating dramatic decreases in the need for therapeutic phlebotomy... 